– IRELAND, Dublin – Open Orphan plc (LON: ORPH | Euronext: ORPH), a rapidly growing specialist contract research organization today announced the appointment of Martin Gouldstone to its Board as an Independent Non-Executive Director effective from 8 June 2022.
“I am pleased to welcome Martin to the Board of Open Orphan. Martin has extensive corporate development experience in the CRO, healthcare and pharmaceutical sectors and held a number of senior roles in healthcare AI businesses. I look forward to working closely with Martin as we drive further growth across the business.” said CEO, Yamin ‘Mo’ Khan.
Martin Gouldstone will also join the Audit & Risk Committee as Chair and the Nominations Committee and the Remuneration Committee as a member.
About Martin Gouldstone
Martin Gouldstone brings 30 years of corporate development experience in the CRO, healthcare, and pharmaceutical sectors, holding several senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion-dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.
Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of CBO at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company’s healthcare practice. Before this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.
Martin Gouldstone commented: “I am delighted to join the Board of Open Orphan at what is an exciting time for the Company and the infectious disease market as it continues to grow significantly post-pandemic. I am delighted to bring my previous three decades of experience in the CRO, healthcare, and pharmaceutical industry to the Company as it continues to build and expand on partnerships with leading global biopharma companies.”
Martin holds a BSc in Genetics and has completed a range of post-graduate management courses.
About Open Orphan plc
Open Orphan plc is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organizations.
The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing several new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK, and medical writing to third party clients as well as supporting the London-based challenge studies.
Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers/patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-center studies.
Building upon its many years of challenging studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.
For more information: https://www.openorphan.com/home
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.